Methodist was the first to report the rapid recovery of patients on ventilators and those with severe medical conditions after three days of treatment. The drug is called RLF-100 and is also known as aviptadil. It has been approved by the FDA for emergency use at multiple clinical sites in patients who are too ill to enter the FDA’s Phase 2/3 trials.
According to a press release from the drug maker NeuroRX, independent researchers have reported that aviptadil blocked replication of the SARS coronavirus in human lung cells and monocytes.
According to the report, a 54-year-old man who contracted COVID-19 while being treated for rejection of a double lung transplant came off a ventilator within four days. According to the report, similar results were seen in more than 15 patients.
The drug appeared to have rapidly cleared pneumonitis findings on an X-ray, improved blood oxygen and a 50% or greater average decrease in laboratory markers associated with COVID-19 inflammation, according to the press release.
"No other antiviral agent has demonstrated rapid recovery from viral infection and demonstrated laboratory inhibition of viral replication," said Prof. Jonathan Javitt, CEO and Chairman of NeuroRx. "We are conducting placebo-controlled trials to see whether the observations made in the case-control and open-label studies will be confirmed for less ill patients with COVID-19-related respiratory failure. Our independent Data Monitoring Committee will be conducting an interim analysis of these data later this month."
Saturday, August 8, 2020
More Unimportant (to the National News Media) COVID-19 News
8/5/20 Channel 2 Houston:
Subscribe to:
Post Comments (Atom)
Thanks for the info. It is now nearing the end of its clinical trial, so results should be interesting.
ReplyDeleteIt was developed as an erectile dysfunction med.